

**Unaudited Financial Statements**

**For The Period 1 August 2018 to 31 December 2019**

**for**

**ARISE PHARMA LTD**

**Contents of the Financial Statements**  
**For The Period 1 August 2018 to 31 December 2019**

	<b>Page</b>
<b>Company Information</b>	<b>1</b>
<b>Balance Sheet</b>	<b>2</b>
<b>Notes to the Financial Statements</b>	<b>4</b>

**ARISE PHARMA LTD**

**Company Information**

**For The Period 1 August 2018 to 31 December 2019**

**DIRECTORS:**

Mrs M Jaykumar Jani  
V B Soni  
J Pradyuman Jani

**SECRETARY:**

J Pradyuman Jani

**REGISTERED OFFICE:**

79 College Road  
Harrow  
Middlesex  
Middlesex  
HA1 1BD

**REGISTERED NUMBER:**

08629933 (England and Wales)

**ACCOUNTANTS:**

Ayman Tyler Associates  
Accountants & Tax Advisers  
79 College Road  
Harrow  
Middlesex  
HA1 1BD

**ARISE PHARMA LTD (REGISTERED NUMBER: 08629933)****Balance Sheet**  
**31 December 2019**

	Notes	31.12.19 £	£	31.7.18 £	£
<b>FIXED ASSETS</b>					
Tangible assets	4		590		1
Investments	5		<u>245,910</u>		<u>246,110</u>
			<b>246,500</b>		<b>246,111</b>
<b>CURRENT ASSETS</b>					
Debtors	6	453,891		204,350	
Cash at bank		<u>184</u>		<u>785</u>	
		<b>454,075</b>		<b>205,135</b>	
<b>CREDITORS</b>					
Amounts falling due within one year	7	<u>383,731</u>		<u>176,012</u>	
<b>NET CURRENT ASSETS</b>			<b>70,344</b>		<b>29,123</b>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			<b>316,844</b>		<b>275,234</b>
<b>CREDITORS</b>					
Amounts falling due after more than one year	8		-		154,619
<b>NET ASSETS</b>			<b>316,844</b>		<b>120,615</b>
<b>CAPITAL AND RESERVES</b>					
Called up share capital			1,000		1,000
Retained earnings			<u>315,844</u>		<u>119,615</u>
<b>SHAREHOLDERS' FUNDS</b>			<b>316,844</b>		<b>120,615</b>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 December 2019.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 December 2019 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The notes form part of these financial statements

**Balance Sheet - continued**  
**31 December 2019**

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 4 March 2021 and were signed on its behalf by:

Mrs M Jaykumar Jani - Director

J Pradyuman Jani - Director

**Notes to the Financial Statements**

**For The Period 1 August 2018 to 31 December 2019**

**1. STATUTORY INFORMATION**

ARISE PHARMA LTD is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

**2. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Turnover**

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc - 33% on cost

**Investments in associates**

Investments in associate undertakings are recognised at cost.

**Taxation**

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

**Deferred tax**

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

**3. EMPLOYEES AND DIRECTORS**

The average number of employees during the period was 2 (2018 - 2) .

**Notes to the Financial Statements - continued**  
**For The Period 1 August 2018 to 31 December 2019**

**4. TANGIBLE FIXED ASSETS**

	<b>Plant and machinery etc £</b>
<b>COST</b>	
At 1 August 2018	857
Additions	879
At 31 December 2019	<u>1,736</u>
<b>DEPRECIATION</b>	
At 1 August 2018	856
Charge for period	290
At 31 December 2019	<u>1,146</u>
<b>NET BOOK VALUE</b>	
At 31 December 2019	<u>590</u>
At 31 July 2018	<u>1</u>

**5. FIXED ASSET INVESTMENTS**

	<b>31.12.19 £</b>	<b>31.7.18 £</b>
Participating interests	18,110	110
Loans to undertakings in which the company has a participating interest	<u>227,800</u>	<u>246,000</u>
	<u><b>245,910</b></u>	<u><b>246,110</b></u>

Additional information is as follows:

	<b>Interest in associate £</b>
<b>COST</b>	
At 1 August 2018	110
Additions	20,000
Disposals	<u>(2,000)</u>
At 31 December 2019	<u>18,110</u>
<b>NET BOOK VALUE</b>	
At 31 December 2019	<u>18,110</u>
At 31 July 2018	<u>110</u>

**Notes to the Financial Statements - continued**  
**For The Period 1 August 2018 to 31 December 2019****5. FIXED ASSET INVESTMENTS - continued**

	<b>Loans to associates £</b>
At 1 August 2018	<b>246,000</b>
New in year	<b>(18,200)</b>
At 31 December 2019	<b><u>227,800</u></b>

In February 2018 the company was allotted 20,000 Ordinary shares of £1 each being a 20% Investment in company Liqmeds Limited. On 31st March 2019, 2,000 Ordinary shares of £1 each representing 2% of the holding were sold for £360,000.

**6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>31.12.19 £</b>	<b>31.7.18 £</b>
Trade debtors	<b>120,000</b>	166,000
Other debtors	<b><u>333,891</u></b>	<u>38,350</u>
	<b><u>453,891</u></b>	<u>204,350</u>

Other Debtors balance is made up of £289,932 loan to LM Manufacturing Ltd, £3,959 expenses paid on behalf of LM Manufacturing Ltd, £30,000 loan to JAJ Pharma Ltd and £10,000 loan to Liqmeds Limited.

**7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>31.12.19 £</b>	<b>31.7.18 £</b>
Trade creditors	-	1
Taxation and social security	<b>25,089</b>	36,156
Other creditors	<b><u>358,642</u></b>	<u>139,855</u>
	<b><u>383,731</u></b>	<u>176,012</u>

Included in Other Creditors is an amount for £164,365 being loan from company Wave Pharma Ltd and £188,440 loan from Mr V B Soni.

**8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR**

	<b>31.12.19 £</b>	<b>31.7.18 £</b>
Other creditors	<b><u>-</u></b>	<u>154,619</u>



This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.